Aurobindo Pharma's wholly-owned subsidiary Aurobindo Pharma Australia Pty has received approval from the Therapeutic Goods Administration (TGA), Government of Australia for the registration of Simvastatin tablets of 5, 10, 20 40 and 80 mg strength. This is its third approval from TGA.
Simvastatin is indicated in patients at high risk of coronary heart disease with or without hypercholesterolemia) and fall under the cardiovascular therapeutic segment.
Aurobindo's robust product portfolio is spread over six major therapeutic/product areas encompassing antibiotics, anti-retrovirals, CVS, CNS, gastroenterologicals and anti-allergics. The company is marketing these products globally, in over 100 countries.